Live Analysis:
Edwards Lifesciences Corporation (EW) is currently priced at $81.77, reflecting a decrease of $1.69 (-2.02%) from the previous close of $83.46. Trading volume stands at $2.62 million, 50.93% above the average.
Earnings Overview:
The latest quarterly earnings report for EW was released on Tuesday, April 21st, with a consensus estimate EPS of 0.72.
Grades:
Barclays maintained an "Overweight" grade for EW on April 27, with the stock price at $84.15.
Cash Flow:
Free cash flow for EW amounts to $353.5 million, with a net change in cash of $244.7 million.
Income Statement:
EW reported a revenue of $1.65 billion and a net income of $380.7 million, resulting in an EPS of 66 cents.
Ratios:
Gross profit margin is at 78.21%, operating profit margin at 31.22%, and net profit margin at 23.09%. The price-earnings ratio stands at 30.46.
Balance Sheet:
Total assets for EW are valued at $13.70 billion, with total liabilities at $3.36 billion.
This comprehensive overview provides insights into the recent performance and financial standing of Edwards Lifesciences Corporation (EW).
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.